

Press Release
03 February 2022 11:00:00 CET



Newbury Pharmaceuticals changes ticker (trading code) to NEWBRY

Newbury Pharmaceuticals has been requested by Nasdaq to change ticker from "NEWBURY" prior to the first day of trading. Consequently, the company has decided to change ticker to "NEWBRY". No other changes have been made from what has been previously communicated and trading will commence tomorrow, February 4, 2022.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury Pharmaceuticals changes ticker \(trading code\) to NEWBRY](#)